Clinical Trials Directory
We are doing this study to find the most effective, safe dose of an experimental drug called INT230-6 (the study drug) in people with recurrent, inoperable, or metastatic soft tissue sarcomas (STS). We also want to know how well it works compared to the usual treatments for people with this diagnosis.
We are using this registry to learn more about acute aortic dissection from hospitals across the country.
We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.
This study begins with a screening period that lasts about 28 days to see if a person can join. If eligible, participants will receive a study medicine called JANX014. This is a new immune based drug that is given through a vein at a clinic or hospital. The medicine may be given once every week, every two weeks, or every three weeks, depending on the study group and safety results. The study has two parts. In the first part, small groups receive different dose levels to find a safe amount of the medicine. In the second part, more people receive selected doses to learn more about safety and early effects. During the study, participants will have regular visits that include physical exams, blood and urine tests, heart tests, and imaging scans such as CT or PET scans. Some early treatment visits may require short hospital stays so doctors can watch closely. Participants may also check their temperature and blood pressure at home.
You will be in this study for about 122 weeks. The study has three parts called Screening, Treatment, and Follow up. During screening, which can last up to six weeks, doctors will do tests to see if you can join. If you qualify, you will be placed by chance into one of two groups. One group will get a study drug called anifrolumab, and the other will get a placebo, which looks like the medicine but has no active drug. You will also keep taking your regular medicines for polymyositis or dermatomyositis. You must stay on the same dose of your regular medicines for at least the first eight weeks of the study.
In this study, people will take a study medicine called JZP 3507 by mouth as tablets. They will take the medicine twice a day for three days in a row each week. This pattern repeats in cycles that last 28 days. The study has several parts, including a screening period to see if someone can join, a treatment period, a safety follow up, and a long term follow up that can last up to three years. The whole study may last about four years and includes many study visits. During the study, participants will have regular checkups such as physical exams, blood and urine tests, heart tests, and scans like MRI. Everyone in the study will receive the study medicine, and both the participant and the doctor will know what treatment is being given.